SCHEMBL22990780

SCHEMBL22990780

Cc1cccc(N(C)C(=O)[C@@H]2CCC(=O)N2C(=O)OCc2ccccc2)c1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
POLQ O75417 3/20 0.49
F10 P00742 2/20 0.45
GFER P55789 2/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.40
NPSR1 Q6W5P4 3/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
GAA P10253 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4382049 1.00 POLQ (0.49) POLQF10GFERPTGDR2NPSR1
SCHEMBL4385663 0.90 F10 (0.50) F10GFERPTGDR2NPSR1KMT2A
SCHEMBL4386402 0.82 GFER (0.58) GFERNPSR1KMT2AMEN1SMN1; SMN2
SCHEMBL4393341 0.80 POLB (0.52) GFERNPSR1KMT2AMEN1GAA
SCHEMBL4391109 0.79 POLB (0.55) POLQF10GFERPTGDR2NPSR1
SCHEMBL22990713 0.78 F10 (0.39) F10PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL29658932 0.78 F10 (0.39) F10PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL15743850 0.78 SMN1; SMN2 (0.48) PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL8290690 0.78 SMN1; SMN2 (0.48) PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL3600152 0.78 SMN1; SMN2 (0.53) NPSR1KMT2AMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer ARTIOS PHARMA LIMITED (GB) 2025-07-15 US disclosed
CN-114667167-B Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-12-20 CN disclosed
EP-4010080-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2023-09-27 EP disclosed
EP-4010080-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2023-09-27 EP disclosed
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-08-03 US disclosed
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-08-03 US disclosed
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-08-03 US disclosed
US-20220298134-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2022-09-22 US disclosed
US-20220298134-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2022-09-22 US disclosed
CN-114667167-A Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2022-06-24 CN disclosed
EP-4010080-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2022-06-15 EP disclosed
WO-2021028643-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER SDHA, SDHB, NQO1 POLQ 328/4885F10 1592/4885GFER 2430/4885
US-20220298134-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER SDHA, SDHB, NQO1 POLQ 328/4885F10 1592/4885GFER 2430/4885
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer SDHA, DPYD, TP53 POLQ 359/4885F10 1915/4885GFER 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.